Phase 3 trial in 18,476 adults aged 18-64: modRNA influenza vaccine had 34.5% relative efficacy vs licensed inactivated vaccine against influenza-like illness (57 vs 87 cases), meeting non-inferiority and superiority; reactogenicity was higher (fever 5.6% vs 1.7%).
Clinical trialn = 18,476
Fitz-Patrick et al. Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine